This trial is active, not recruiting.

Condition psoriasis vulgaris
Treatments ketokonazol 2% cream, uvb-radiation 311nm
Phase phase 2
Sponsor Technische Universität Dresden
Start date March 2008
End date October 2009
Trial size 12 participants
Trial identifier NCT00678756, TUD-VITAKET


Exploration of antipsoriatic effects of UVB-therapy +/- CYP-inhibitor Ketokonazol on affected psoriatic skin

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking open label
Primary purpose treatment

Primary Outcomes

time frame: 4 weeks

Secondary Outcomes

OCT/ultrasound- thickness of epidermis/ dermis
time frame: 4 weeks

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - age: 18- 80 - diagnosis of psoriasis vulgaris (mild- middle) - no other current antipsoriatic therapy (systemic/topical) - at least 5 psoriatic areas of 5x5 cm Exclusion Criteria: - pregnancy/nursing mothers - women in reproductive age without adequate contraception - severe and acute forms of psoriasis vulgaris - patients receiving systemic or topical antipsoroatic treatment in past 3 month - UV-therapy in past 3 month - patients having a positive anamnesis for squamous cell carcinoma, malignant melanoma, basalioma - epilepsy

Additional Information

Official title Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol
Principal investigator Gottfried Wozel, Prof. Dr.med
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by Technische Universität Dresden.